Review Stresses Biomedical Applications for Designed DNA Nanostructures
|
By LabMedica International staff writers Posted on 05 Oct 2015 |

Image: Virus-protein-coated DNA origami nanostructures. With the help of protein encapsulation, such nanostructures can be transported into human cells much more efficiently (Photo courtesy of Dr. Veikko Linko and Dr. Mauri Kostiainen, Aalto University).
A recent review article described how self-assembled DNA nanostructures could be used in molecular-scale diagnostics and as smart drug-delivery vehicles.
Investigators at Aalto University (Finland) described in the October 2015 issue of the journal Trends in Biotechnology how DNA molecules could be assembled into tailored and complex nanostructures, and how such structures could be used for bio-nanotechnological applications such as molecular diagnostics and targeted therapeutics.
The authors said that DNA molecules can be assembled into custom predesigned shapes via hybridization of sequence-complementary domains. The folded structures have high spatial addressability and tremendous potential to serve as platforms and active components in a plethora of bio-nanotechnological applications. They stressed that DNA is a truly programmable material, and its nanoscale engineering opens up numerous attractive possibilities to develop novel methods for therapeutics. Furthermore, tailored molecular devices could be used to target cells and trigger cellular actions in the biological environment.
"Nowadays, software and techniques to design and simulate DNA nanostructures are extremely powerful and user-friendly, and thus, researchers can easily construct their own DNA-objects for various uses. The big boom in the field of structural DNA nanotechnology happened in 2006, when Paul Rothemund introduced a technique dubbed "DNA origami". This method is the starting point for practically all other straightforward design approaches available today", said first author Dr. Veikko Linko, a postdoctoral researcher in biohybrid materials at Aalto University.
Related Links:
Aalto University
Investigators at Aalto University (Finland) described in the October 2015 issue of the journal Trends in Biotechnology how DNA molecules could be assembled into tailored and complex nanostructures, and how such structures could be used for bio-nanotechnological applications such as molecular diagnostics and targeted therapeutics.
The authors said that DNA molecules can be assembled into custom predesigned shapes via hybridization of sequence-complementary domains. The folded structures have high spatial addressability and tremendous potential to serve as platforms and active components in a plethora of bio-nanotechnological applications. They stressed that DNA is a truly programmable material, and its nanoscale engineering opens up numerous attractive possibilities to develop novel methods for therapeutics. Furthermore, tailored molecular devices could be used to target cells and trigger cellular actions in the biological environment.
"Nowadays, software and techniques to design and simulate DNA nanostructures are extremely powerful and user-friendly, and thus, researchers can easily construct their own DNA-objects for various uses. The big boom in the field of structural DNA nanotechnology happened in 2006, when Paul Rothemund introduced a technique dubbed "DNA origami". This method is the starting point for practically all other straightforward design approaches available today", said first author Dr. Veikko Linko, a postdoctoral researcher in biohybrid materials at Aalto University.
Related Links:
Aalto University
Latest BioResearch News
- Study Reveals Diagnostic and Therapeutic Target in Rare Pancreatic Tumors
- Researchers Identify Survival Pathway Undermining Targeted Cancer Drugs
- Large-Scale Study Maps DNA Damage Signatures Across Multiple Cancers
- Study Identifies Distinct Immune Signatures to Early Depression and Psychosis
- Genetic Mutation Behind Aggressive Adult Leukemia Offers Treatment Clues
- Disease Gene Discovery Advances Diagnosis of Rare Movement Disorders
- Genetic Discovery Could Improve Diagnosis of Drug-Resistant Epilepsy
- Genetic Discovery May Improve Diagnosis of Rare Dementia Subtype
- Mass Spectrometry Technique Detects Protein and Sugar Changes in Neurodegeneration
- Barcoded DNA Sheds Light on Hidden Complexities in Breast Cancer Detection
- CRISPR-Based Platform Pinpoints Drivers of Acute Myeloid Leukemia in Patient Cells
- Protective Brain Protein Emerges as Biomarker Target in Alzheimer’s Disease
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
Channels
Clinical Chemistry
view channel
New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
Steroid hormone measurement is a core application of clinical mass spectrometry, which is widely regarded as a diagnostic gold standard. Access to these high-specificity methods has often been constrained... Read more
Study Shows Dual Biomarkers Improve Accuracy of Alzheimer’s Detection
Alzheimer’s disease develops slowly, and biological changes can appear in blood many years before symptoms. While plasma assays for phosphorylated tau offer earlier detection, discerning whether these... Read moreMolecular Diagnostics
view channel
New Molecular Test Boosts Accuracy of Bile Duct Cancer Diagnosis
Bile duct strictures can arise from cancer or benign disease, but their location within ducts connecting the liver, gallbladder, and intestines complicates evaluation. Standard biopsy and cytology may... Read moreAdaptive PCR Platform Improves Consistency in Small-Batch NGS Workflows
PCR amplification during next-generation sequencing (NGS) library preparation can introduce variability, often requiring manual quantification and risking over-cycling artifacts. The issue is especially... Read more
First IVDR‑Certified IGH Clonality Assay Supports Diagnosis of B-Cell Malignancies
Accurate identification of clonal immunoglobulin heavy chain (IGH) gene rearrangements is central to evaluating suspected B-cell lymphoproliferative disorders, where a single B-cell clone yields a defining... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
Rapid Urine Test Speeds Antibiotic Selection for UTIs
Urinary tract infections are a common reason for antibiotic prescribing and have led to more than 800,000 hospital admissions across England in the past five years, according to National Health Service data.... Read more
WHO Endorses Rapid Point-of-Care Testing to Improve TB Detection
Tuberculosis (TB) remains a leading infectious killer, with more than 3,300 deaths and 29,000 new illnesses every day. Diagnostic delays and dependence on centralized laboratory networks continue to impede... Read morePathology
view channel
AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer remains a difficult decision because only a subset benefits and many undergo toxicity without gain. Genomic assays can help but are costly,... Read more
Biopsy-Based Gene Test Predicts Recurrence Risk in Lung Adenocarcinoma
Lung cancer is the leading cause of cancer death, killing more people in the United States than breast, prostate, and colon cancers combined. In lung adenocarcinoma (LUAD), tumors that invade nearby blood... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel
Lunit and CellCarta Collaborate to Expand AI Pathology in CDx Development
Lunit (Seoul, South Korea), a leading provider of AI for cancer diagnostics and precision oncology, and CellCarta (Montreal, QC, Canada), a global contract research organization (CRO) laboratory serving... Read more








